<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02966301</url>
  </required_header>
  <id_info>
    <org_study_id>GMED16-001</org_study_id>
    <nct_id>NCT02966301</nct_id>
  </id_info>
  <brief_title>Treatment of Chronic Graft Versus Host Disease With Arsenic Trioxide</brief_title>
  <acronym>GvHD-ATO</acronym>
  <official_title>Phase II Study of First Line Treatment of Chronic Graft Versus Host Disease With Arsenic Trioxide</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medsenic</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fovea</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medsenic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate the early chronic GvHD events (first line therapy), if the
      addition of arsenic trioxide to standard therapy with corticosteroids, with or without
      cyclosporine, will be effective in controlling chronic GvHD and to reduce the duration of
      corticosteroid therapy
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Graft-versus-host disease (GvHD) is the most common long-term complication in patients who
      underwent allogeneic transplantation.

      First-line therapy for chronic GVHD is based on immunosuppressive agents (corticosteroids
      with or without cyclosporine) achieving satisfactory response in around 30% of patients.

      This is a prospective, national, multicenter, non-randomized Phase II study that will include
      a total number of 24 patients in which, trioxide d'arsenic will be administrated at
      0,15mg/kg/day.

      Clinical response will be evaluated based on the Working Group Report 2015, published by the
      National Institute of Health Consensus.

      Follow-up visits will be weekly for four weeks (ATO cycle), every two weeks from second to
      third month of ATO treatment, every month from the fourth to sixth month of ATO treatment and
      every 3 months, at 9 months and 12 months (final visit).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with complete or partial remission of Chronic Graft versus Host Disease after a first line treatment with Arsenic Trioxide</measure>
    <time_frame>six months</time_frame>
    <description>Clinical response will be evaluated based on the Working Group Report 2015, published by the National Institute of Health Consensus : Lee SJ et al. Biol Blood Marrow Transplant, 2015 (cGvHD activity assessment Clinician Form A &amp; cGvHD assessment patient self-report Form B)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Steroid dose reduction (mg/kg/day of prednisone)</measure>
    <time_frame>2 weeks and 3, 6, 9 &amp; 12 months after ATO cycle treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life self-reported by patient using the Lee Symptom Scale (LSS)</measure>
    <time_frame>6 &amp; 14 week, 6, 9 &amp; 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life self-reported by patient using the Functional Assessment of Chronic Illness : Therapy with Bone Marrow Transplantation subscale (FACT-BMT)</measure>
    <time_frame>6 &amp; 14 week, 6, 9 &amp; 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time without relapse in case of positive response</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival rates</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>12 months</time_frame>
    <description>Follow-up throughout the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood test of immunoglobulins</measure>
    <time_frame>Inclusion, 6 &amp; 14 week, 6, 9 &amp; 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood test of arsenic</measure>
    <time_frame>D2, D3, D4, D5, D8, D12, D17 and D24, during arsenic trioxide treatment period</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Chronic Graft-Versus-Host Disease</condition>
  <condition>Immune System Diseases</condition>
  <arm_group>
    <arm_group_label>interventional</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single arm : Arsenic trioxide Injectable Solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arsenic Trioxide Injectable Solution</intervention_name>
    <description>Each patient will receive eleven perfusions of arsenic trioxide (0,15 mg/kg/Day - IV administration) over a 4 weeks period (one cycle).
Patients in partial response after the 1st cycle of ATO will be eligible to receive a second cycle of ATO as consolidation therapy. A delay of 8 weeks (from the first infusion of ATO) will be observed between the two cycles of ATO therapy.
The study duration will be 2 years (12 months recruitment + 12 months follow-up).</description>
    <arm_group_label>interventional</arm_group_label>
    <other_name>Trisenox</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients (≥18 years) who have received a first allogeneic stem cell
             transplantation for a hematological disease (any source of hematopoietic stem cells is
             authorized; any category of conditioning regimen prior to allo-SCT is authorized; any
             type of stem cell donors is authorized)

          -  Confirmed diagnosis of a first episode of chronic GvHD requiring systemic
             immunosuppressive therapy (any prior GvHD prophylaxis previously used is accepted).
             Chronic GvHD diagnosis is defined according to the NIH Working Group Consensus.
             Chronic GvHD diagnosis will be based on the evaluation of the severity of the
             different clinical manifestations including:

               -  Performance status evaluation

               -  Cutaneous evaluation measured by the percentage of extension or the presence of
                  sclerotic features. If relevant, confirmation with a biopsy should be performed
                  whenever possible

               -  Oral symptoms

               -  Ocular symptoms

               -  Gastro-intestinal symptoms

               -  Evaluation of liver involvement (total bilirubin, transaminases and alkaline
                  phosphatases)

               -  Pulmonary function evaluation

               -  Evaluation of the musculoskeletal manifestations, especially the amplitude of the
                  relevant articulations

               -  Genital tract symptoms

          -  Signed informed consent

          -  Absence of contra-indications to the use of ATO

          -  Subjects affiliated with an appropriate social security system

          -  Men must use a medically acceptable method of contraception throughout the treatment
             period and for at least 4 months and 10 days following the last treatment
             administration

          -  Women who are of childbearing potential must have a negative serum pregnancy test and
             agree to use a medically acceptable method of contraception throughout the study and
             for 3 months following the end of the study

          -  Patient not participating or not having participated in a clinical study in the 30
             days prior to his/her inclusion in the study

        Exclusion Criteria:

          -  Patient developing acute GvHD (whether early or &quot;late onset&quot; form)

          -  Patients developing overlap GvHD as defined by the 2014 NIH Working Group Consensus
             (presence of one or more acute GvHD manifestations in a patient with a diagnosis of
             chronic GvHD)

          -  A &quot;mild&quot; form of chronic GvHD not requiring systemic immunosuppressive therapy

          -  A &quot;moderate&quot; form of chronic GvHD limited to one organ site not requiring systemic
             immunosuppressive therapy

          -  Patient receiving mycophenolate mofetil

          -  GvHD occurring following donor lymphocytes infusion (DLI)

          -  Not the first episode of chronic GvHD needing systemic immunosuppressive therapy

          -  Second allogeneic stem cell transplant

          -  Severe cardiac diseases (congestive heart failure (NYHA class III), recent myocardial
             infarction (in the past 6 months before the inclusion), histories of unexplained
             syncope, ...)

          -  Significant arrhythmias, electrocardiogram (EKG) abnormalities:

          -  Congenital QT syndromes

          -  History or presence of significant ventricular or atrial tachyarrhythmia

          -  Clinically significant resting bradycardia (&lt; 50 beats per minutes)

          -  QTc&gt;450msecformenand&gt;470msecfor women on screening EKG (using the QTcF formula)

          -  Right bundle branch block plus left anterior hemiblock, bifascicular block

          -  Central or peripheral neuropathy

          -  Neutrophils &lt; 0.5 × 109/L

          -  Platelets &lt; 50 × 109/L

          -  Potassium ≤ 4 mEq/l

          -  Magnesium ≤ 1.8 mg/dl

          -  Calcium ≤ 2.15 mmol/l

          -  Hepatic impairment (PT &lt;50% or SGOT or SGPT or alkaline phosphatases ≥ 2N)

          -  Renal impairment (creatinine ≥ 100 μmol/l)

          -  Uncontrolled systemic infection which in the opinion of the investigator is associated
             with an increased risk of the patients' death within 1 month after the start of
             therapy

          -  Severe neurological or psychiatric disorders

          -  Denied informed consent

          -  Pregnancy

          -  Women breastfeeding at selection and throughout the treatment period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohamad Mohty, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Saint-Antoine, AP-HP - Paris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anne Huyhn, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Universitaire du Cancer - Oncopole - Toulouse</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sylvain Chantepie, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut d'Hématologie de Basse Normandie - CHU de Caen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Patrice Chevallier, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôtel Dieu - CHU Nantes</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Catherine Faucher, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Paoli Calmettes - Centre de Recherche en Cancérologie de Marseille</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Patrice Ceballos, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital St Eloi - Montpellier</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Patrice Turlure, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Limoges</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Réza Tabrizi, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Bordeaux</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>François Rieger, Pr</last_name>
    <phone>0671733159</phone>
    <phone_ext>+33</phone_ext>
    <email>fr@medsenic.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Véronique Pomi</last_name>
    <phone>0635463266</phone>
    <phone_ext>+33</phone_ext>
    <email>veronique.pomi@medsenic.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU - Département d'Hématologie Clinique et Thérapie Cellulaire</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Réda Tabrizi, Dr</last_name>
      <email>reda.tabrizi@chu-bordeaux.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Caen - Institut d'Hématologie de Basse Normandie</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sylvain Chantepie, Dr</last_name>
      <phone>02 31 06 48 49</phone>
      <phone_ext>+33</phone_ext>
      <email>chantepie-s@chu-caen.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU - Département d'Hématologie Clinique et Thérapie Cellulaire</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmettes - Département d'hématologie - Centre de Recherche en Cancérologie de Marseille</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Catherine Faucher, Dr</last_name>
      <phone>04 91 22 37 54</phone>
      <phone_ext>+33</phone_ext>
      <email>faucherc@ipc.inucancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital St Eloi - Service d'Hématologie Clinique</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Hôtel Dieu - Service Hématologie Clinique</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrice Chevallier, Pr</last_name>
      <phone>02 44 08 32 64</phone>
      <phone_ext>+33</phone_ext>
      <email>patrice.chevallier@chu-nantes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Antoine - Hématologie et thérapie cellulaire - AP-HP</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Universitaire du Cancer - Oncopole - Service d'Hématologie</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Huynh, Dr</last_name>
      <phone>05 31 15 50 50</phone>
      <phone_ext>+33</phone_ext>
      <email>Huynh.Anne@iuct-oncopole.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 28, 2016</study_first_submitted>
  <study_first_submitted_qc>November 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 17, 2016</study_first_posted>
  <last_update_submitted>July 3, 2017</last_update_submitted>
  <last_update_submitted_qc>July 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>c GvHD</keyword>
  <keyword>Arsenic Trioxyde</keyword>
  <keyword>Hematology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Graft vs Host Disease</mesh_term>
    <mesh_term>Immune System Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arsenic trioxide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

